Madrigal Pharmaceuticals, Inc. (MDGL) Financials
MDGL Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 1.2 billion | 720.9 million |
| March 31, 2026 | 1.2 billion | 683.9 million |
| Dec. 31, 2025 | 1.3 billion | 656.9 million |
| Sept. 30, 2025 | 1.4 billion | 736.7 million |
MDGL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 19.1 million | 35.4 million |
| March 31, 2026 | -171.3 million | 34.0 million |
| Dec. 31, 2025 | -133.1 million | 25.8 million |
| Sept. 30, 2025 | 79.0 million | 26.3 million |
MDGL Net Income
No data available :(
MDGL Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 838.8 million | 340.8 million | 5.9 million |
| March 31, 2026 | 817.9 million | 340.3 million | 5.3 million |
| Dec. 31, 2025 | 983.6 million | 346.6 million | 6.7 million |
| Sept. 30, 2025 | 1.1 billion | 339.8 million | 6.6 million |
MDGL Shares Outstanding
MDGL Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 4.3 million | 91.2 million | 289.4 million | - |
| March 31, 2026 | 3.8 million | 108.7 million | 268.5 million | - |
| Dec. 31, 2025 | 390000 | 116.3 million | 240.0 million | - |
| Sept. 30, 2025 | 857000 | 174.0 million | 209.1 million | - |
MDGL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 364.3 million | 40.0 million |
| March 31, 2026 | 311.3 million | 26.8 million |
| Dec. 31, 2025 | 321.1 million | 24.4 million |
| Sept. 30, 2025 | 287.3 million | 18.1 million |
MDGL Revenue by Segment
Graph available only for paid members. Upgrade to see it.
MDGL
Price: $471.75
52 week price:
Earnings Per Share: -14.41 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 132314
Ebitda: -8.4 millionMarket Capitalization: 11.5 billion